心脏移植受者供体传播冠状动脉疾病的患病率、特征及预后意义
该回顾性多中心研究纳入2008-2018年西班牙11个中心1918例成人心脏移植患者,其中937例在移植后3个月内接受冠状动脉造影。供体传播冠状动脉疾病(TCAD)患病率为18.3%,显著TCAD(狭窄≥50%)占6.9%。显著TCAD与全因死亡率无显著关联,但独立预测心血管死亡和心血管死亡或非致命性MACE复合事件。
要点
- TCAD患病率18.3%,其中显著TCAD(狭窄≥50%)占6.9%。
- 显著TCAD独立预测心血管死亡(校正HR 2.25)和心血管死亡或非致命性MACE(校正HR 2.42)。
- 非显著TCAD(狭窄<50%)未显示与临床结局的显著关联。
核心结论
- 在移植后3个月内接受冠状动脉造影的心脏移植受者中,TCAD与生存率降低无关,但显著TCAD患者心血管死亡和MACE风险增加。
研究设计与样本
- 回顾性研究纳入2008至2018年西班牙11个中心连续接受心脏移植的1918例>18岁患者,其中937例在移植后3个月内接受冠状动脉造影。
- 显著TCAD定义为心外膜冠状动脉任何狭窄≥50%,非显著TCAD定义为狭窄<50%。
- 采用Cox回归和竞争风险回归评估临床结局,冠状动脉造影后中位随访6.3年。
主要发现
- 172例(18.3%)发现TCAD,其中显著TCAD 65例(6.9%),非显著TCAD 107例(11.4%)。
- 多变量Cox回归显示显著TCAD与全因死亡率无统计学显著关联(校正HR 1.44;95%CI 0.89-2.35;P=0.141)。
- 显著TCAD是心血管死亡的独立预测因子(校正HR 2.25;95%CI 1.20-4.19;P=0.011)。
- 显著TCAD是心血管死亡或非致命性MACE复合事件的独立预测因子(校正HR 2.42;95%CI 1.52-3.85;P<0.001)。
- 非显著TCAD未显示对临床结局有统计学显著影响,竞争风险回归结果相似。
临床怎么用
- 对于心脏移植后3个月内接受冠状动脉造影的患者,应识别显著TCAD(狭窄≥50%)以评估心血管死亡和MACE风险。
- 显著TCAD患者可能需要更密切的心血管风险监测和管理。
局限性
- 回顾性研究设计。
- 仅纳入移植后3个月内接受冠状动脉造影的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The reported prevalence of donor-transmitted coronary artery disease (TCAD) in heart transplantation (HT) is variable, and its prognostic impact remains unclear. OBJECTIVES: The goal of this study was to characterize TCAD in a contemporary multicentric cohort and to study its prognostic relevance. METHODS: This was a retrospective study of consecutive patients >18 years old who underwent HT in 11 Spanish centers from 2008 to 2018. Only patients with a coronary angiography (c-angio) within the first 3 months after HT were studied. Significant TCAD (s-TCAD) was defined as any stenosis ≥50% in epicardial coronary arteries, and nonsignificant TCAD (ns-TCAD) as stenosis <50%. Clinical outcomes were assessed by means of Cox regression and competing risks regression. Patients were followed-up for a median period of 6.3 years after c-angio. RESULTS: From a cohort of 1,918 patients, 937 underwent c-angio. TCAD was found in 172 patients (18.3%): s-TCAD in 65 (6.9%) and ns-TCAD in 107 (11.4%). Multivariable Cox regression analysis did not show a statistically significant association between s-TCAD and all-cause mortality (adjusted HR: 1.44; 95% CI: 0.89-2.35; P = 0.141); however, it was an independent predictor of cardiovascular mortality (adjusted HR: 2.25; 95% CI: 1.20-4.19; P = 0.011) and the combined event cardiovascular death or nonfatal MACE (adjusted HR: 2.42; 95% CI: 1.52-3.85; P < 0.001). No statistically significant impact of ns-TCAD on clinical outcomes was detected. The results were similar when reassessed by means of competing risks regression. CONCLUSIONS: TCAD was not associated with reduced survival in patients alive and well enough to undergo post-HT angiography within the first 3 months; however, s-TCAD patients showed increased risk of cardiovascular death and MACE.
引用
- Couto-Mallón D, Almenar-Bonet L, Barge-Caballero E, et al. Prevalence, Characteristics, and Prognostic Relevance of Donor-Transmitted Coronary Artery Disease in Heart Transplant Recipients. J Am Coll Cardiol. 2023. PMID: 37612006. doi:10.1016/j.jacc.2023.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。